Evaluation of the hypolipidemic activity of xenalipin in experimental animals.
Xenalipin (4'-trifluoromethyl-2-biphenylcarboxylic acid) is a chemically novel compound which has been found to be an effective hypolipidemic agent in two animal species. Significant reductions in serum cholesterol and triglycerides were observed in cholesterol-cholic acid-fed rats following oral doses of 10-30 mg/kg/day. Xenalipin was considerably more potent than clofibrate, nicotinic acid, and cholestyramine in the same model. Lipoprotein analysis showed that xenalipin reduced cholesterol and protein content in very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL). Triglycerides were reduced in VLDL and IDL. Xenalipin was also effective in reducing serum cholesterol and triglyceride concentrations in normocholesterolemic rats. In diet-induced hypercholesterolemic African green monkeys, xenalipin at oral doses of 15-60 mg/kg b.i.d. reduced serum LDL-cholesterol concentrations. These results suggest that xenalipin has a profile of activity which would be beneficial in therapy for hyperlipidemia.
M C
MC
Lewis
G L
GL
Hodgson
T K
TK
Shumaker
D H
DH
Namm
D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D002522:Chlorocebus aethiops; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000494:pharmacology; D019826:Cholic Acid; D002793:Cholic Acids / Q000494:pharmacology; D006937:Hypercholesterolemia / Q000097:blood; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values
D001713:Biphenyl Compounds; D002791:Cholesterol, Dietary; D002793:Cholic Acids; D008055:Lipids; D008074:Lipoproteins; C052519:xenalipin; D002784:Cholesterol; D019826:Cholic Acid